ReviewJournal of the Egyptian National Cancer Institute2026
Head and neck cancer: a comprehensive review of epidemiology, global burden and advances in radiotherapy.
Review in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck cancer (HNC), a heterogeneous group of malignancies that arising from the mucosal surfaces of the Upper Aerodigestive Tract (UADT), is a major health concern worldwide. By 2050, the number of cancer cases worldwide is expected to reach 35 million, with nearly half of all new cases and deaths occurring in Asia. In India, HNC is particularly prevalent accounting for about 30% of the global burden, with lip and oral cavity cancers (OCC) make up 10.17% of all cases, highlighting a serious public health crisis. A comparative analysis of GLOBOCAN 2022 data reveals a significant variation in HNC burden; India's overall Age-Standardized Incidence Rate (ASIR) for lip and OCC is 9.8, which is considerably higher than the Asian average of 3.2 and the global average of 4.1. Indian males facing a particularly high burden (ASIR: 14.7) compared to females (ASIR: 4.9). While India leads in sites such as the larynx and hypopharynx, it maintains a notably lower burden of nasopharyngeal cancer (ASIR: 0.4) compared to the rest of Asia (ASIR: 1.9). High Mortality-to-Incidence Ratio (MIR) persist across all sub-sites, with tobacco, alcohol, and Human Papillomavirus (HPV) being the main risk factors. This review critically analyses HNC literature by integrating historical perspectives with recent progress in radiation therapy (RT). This includes Three- Dimensional Conformal Radiation Therapy (3DCRT), Intensity- Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Volumetric Modulated Arc Therapy (VMAT), and new methods like Stereotactic Radiosurgery (SRS), Stereotactic Radiotherapy (SRT), Stereotactic Body Radiation Therapy (SBRT), Tomotherapy, Proton therapy (PT) and Adaptive Radiotherapy (ART). Radiotherapy remains a cornerstone of treatment, with its success relying on precise technology and accurate treatment delivery. By analysing epidemiology, risk factors, and evolving clinical approaches, this work creates a clear framework for current management and highlights future directions to improve patient quality of life and treatment results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.